Allegra Faces Increasing Challenges In Rx Drug Arena
This article was originally published in The Tan Sheet
Executive Summary
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis
You may also be interested in...
Aventis “Contingency Plans” For Allegra Include Outlicensing
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status
Aventis “Contingency Plans” For Allegra Include Outlicensing
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status
Aventis “Contingency Plans” For Allegra Include Outlicensing
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status